Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to assess the safety, tolerability and pharmacokinetics of
Hemay022. The secondary purpose of this study is to assess the efficacy of Hemay022 in the
treatment of HER2-positive advanced breast cancer.
The study will be conducted in two parts. Part one, trial will be conducted in 18-30 subjects
to determine safety and tolerability of Hemay022 in patients with HER2-positive advanced
breast cancer. Part two, approximately 27 additional subjects with HER2-positive advanced
breast cancer, are included to better define the tolerability and preliminary efficacy of
Hemay022.